Anne Brunet
Brunet helped establish FOXO and SIRT1 as central molecular links between stress responses and longevity. Her 253 papers have drawn more than 52,000 citations.
Profile
Professor of Genetics at Stanford University whose laboratory investigates the genetic and epigenetic mechanisms that govern aging and longevity, with work spanning model organisms, stem cells, and rejuvenation.
Role
scientisthigh confidence
Brunet co-authored peer-reviewed aging and longevity papers that experimentally investigate epigenetic longevity regulation and partial reprogramming in aged mouse brain tissue. This primary research is the evidenced channel through which she advances longevity.
Dimension breakdown
This score rates longevity commitment only. The role tags above — scientist, investor, and the rest — say what this person is; we don't score those separately.
Future vision
7.0/ 10
Brunet articulates a durable, scientifically grounded vision of delaying and potentially reversing aspects of aging through epigenetic reprogramming, stem-cell rejuvenation, and targeted geroscience interventions. Her vision identifies concrete mechanisms and desired human-health outcomes, especially preventing cognitive decline and extending tissue healthspan. It falls short of a field-defining score because the evidence does not show a comprehensive roadmap, timeline, explicit commitment to ending aging, or a clearly unified public theory of radical human lifespan extension.
medium confidence
Scientific impact
9.5/ 10
Primary bibliometric evidence indicates field-defining scientific influence. Brunet has an h-index of 92 and 52,133 citations, with multiple foundational papers on Akt, FOXO, SIRT1, and geroscience receiving thousands of citations. Her continuing work spans core longevity mechanisms and emerging aging-research methods, although the evidence does not establish clinical translation.
high confidence
Capital deployed
N/A
Anne Brunet is evidenced here as a longevity scientist, but there are no identified investments, donations, or capital-backed outcomes to evaluate. Her substantial scientific output does not constitute capital deployment under this rubric.
No public investment or donation activity is evidenced, so capital deployment is inapplicable.
high confidence
Strategic taste
6.0/ 10
Brunet shows a coherent scientific thesis around genetic and epigenetic control of longevity, including early work on FOXO/SIRT1 and a notable pursuit of controversial transgenerational epigenetic inheritance. These choices appear scientifically prescient and helped develop important aging-research paths, but the supplied evidence does not establish explicit thesis formation, unusual risk-taking, or a strong counterfactual case that her choices uniquely redirected the field.
medium confidence
Field creation
1.0/ 10
The dimension applies, but the supplied evidence documents scientific research rather than creation of organizations, programs, communities, protocols, categories, or funding paths. The structured facts explicitly report no founded organizations or donation-created programs.
high confidence
Bravery and conviction
1.0/ 10
The dimension applies, but the supplied evidence documents scientific productivity and longevity research rather than public risk-taking or conviction. No evidence demonstrates a contrarian stance, career sacrifice, a personally significant bet, persistence under serious criticism, or self-experimentation.
high confidence
Multiplier effect
6.0/ 10
Brunet demonstrates substantial academic multiplier effects through exceptionally high citation impact and collaborations spanning institutions and disciplines. This indicates that her research has enabled significant follow-on scholarship and attracted collaborators, although the evidence does not establish comparable leverage through organization-building, capital, policy, entrepreneurship, or public mobilization.
medium confidence
Vision
Destination
Our work suggests a mechanism for the evolution of complex adaptations and offers strategies to promote long-term survival by activating suspended animation programs in other species.
Understanding the mechanisms that drive stem cell aging and how to counteract them is a critical step for enhancing tissue repair and maintenance during aging.
it is critical to expand geroscience research directed at extending human healthspan.
Finally, we argue that reprogramming provides a unique opportunity to model aging and perhaps exceptional longevity.
In mammals, we also identified the functional mechanisms that influence regenerative pools of stem cells, notably in the brain, with the goal of reverting features of brain aging and preventing cognitive decline.
Path
Our work suggests that partial reprogramming could be used to rejuvenate the neurogenic niche and counter brain decline in old individuals.
The potential reversibility of these epigenetic changes that occur as a hallmark of aging offers exciting opportunities to alter the trajectory of age-related diseases.
Her lab is interested in identifying pathways involved in delaying aging in response to external stimuli such as availability of nutrients and mates.
She also seeks to understand the mechanisms that influence the rejuvenation of old stem cells.
Understanding the intricate signaling networks that translate environmental conditions like dietary restriction into changes in gene expression that extend lifespan will be of critical importance to identify ways to delay the onset of aging and age-dependent diseases.
Strategy
No evidence was available to establish Anne Brunet’s investment, philanthropic, or organizational strategy [S1]. Her documented research focuses on the genetic and epigenetic mechanisms governing aging and longevity [S1]. That work spans model organisms, stem cells, and rejuvenation, but it does not establish a preferred funding stage, geography, risk appetite, or time horizon [S1]. No notable bets or evidence-backed collaborators can be identified from the supplied material [S1].
UnknownUnknownGenetics Of AgingEpigeneticsStem CellsRejuvenationModel Organisms
Portfolio
Investments
No public rows yet.
Donations
No public rows yet.
Organizations founded
No public rows yet.
Scientific output
h-index92
Citations-
Papers26
Trials0
Belief evolution
Connections
Companies
Collaborators and lineage
No public rows yet.
Criticisms